One of our clients was planning a phase 2a safety, tolerability, pharmacokinetic, and pharmacodynamic study in individuals with MELAS, a rare disease that primarily affects the nervous system and muscles. The study was looking to enroll US candidates who would agree to participate in a 29-day treatment plan and a 14-day follow-up visit. The client’s target enrollment was 20 patients.

To overcome this challenge, the Jumo Health team produced educational resources for patients throughout all phases: pre-consent, screening, and enrollment. Each product developed helped explain the study, outline the participant’s appointment schedule, and set expectations in a visually engaging, easily understandable, empowering, and relatable way that spoke directly to this small patient population.